HER2-directed antibody-drug conjugate (RC48) that binds HER2 on tumor cells, is internalized, and releases the microtubule inhibitor MMAE to disrupt microtubules and induce apoptosis.
HER2-targeted antibody-drug conjugate (RC48) that binds HER2 on tumor cells, is internalized, and releases the microtubule inhibitor monomethyl auristatin E (MMAE); MMAE inhibits tubulin polymerization, leading to G2/M cell-cycle arrest and apoptosis in HER2-expressing cells.
YES
DIRECT
The ADC binds HER2 on target cells, is internalized, and releases MMAE, which inhibits tubulin polymerization, leading to G2/M arrest and apoptosis of HER2-expressing cells.
HER2-directed antibody-drug conjugate (RC48) that binds HER2 on tumor cells, is internalized, and releases the microtubule inhibitor MMAE to disrupt microtubules and induce apoptosis.
HER2-targeted antibody-drug conjugate (RC48) that binds HER2 on tumor cells, is internalized, and releases the microtubule inhibitor monomethyl auristatin E (MMAE); MMAE inhibits tubulin polymerization, leading to G2/M cell-cycle arrest and apoptosis in HER2-expressing cells.
NO
INDIRECT
The ADC binds HER2 on tumor cells, is internalized, and releases MMAE, which then binds the beta‑tubulin (vinca domain) to inhibit microtubule polymerization, causing G2/M arrest and apoptosis in HER2-positive cells; beta‑tubulin itself is not the targeting determinant.
Off-the-shelf, allogeneic, lentiviral-engineered double-negative T cells (DNTs) expressing an anti-CD19 chimeric antigen receptor (CAR) to target and kill CD19-positive malignant B cells.
Off-the-shelf allogeneic double-negative T cells engineered with an anti-CD19 chimeric antigen receptor bind CD19 on malignant B cells; CAR signaling activates the DNTs to exert cytotoxicity and eliminate CD19-positive tumor cells.
YES
DIRECT
Anti-CD19 CAR-expressing double-negative T cells bind CD19+ cells and, upon CAR signaling, kill them via T-cell cytotoxic pathways (perforin/granzyme and Fas–FasL-mediated apoptosis).
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal IgG directed against multiple T-cell antigens that binds and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis, leading to immunosuppression and GVHD prophylaxis.
YES
DIRECT
Antithymocyte globulin binds CD2 on T cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC, and can trigger apoptosis, leading to depletion of CD2+ cells.